Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KURAthis companyKura Oncology, Inc.	$7.63	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
BBOTBridgeBio Oncology Therapeutics Inc.	$2.18	-2.91×	0.95×	0×	-0.13×	414.3%	0.0%	0.0%	0.0%	-32.6%	-35.2%	-29.4%	0.01×	2.55×	0×	12.14×	0.0%	0	-0.72	3	B
CRDFCardiff Oncology, Inc.	$0.81	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
NRIXNurix Therapeutics, Inc.	$16.09	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
ORICORIC Pharmaceuticals, Inc.	$9.28	-5.56×	1.87×	0×	-5.33×	-96.2%	0.0%	0.0%	0.0%	-33.7%	-36.3%	-15.9%	0.03×	0.27×	0×	14.13×	0.0%	1	21.2	2	C
RIGLRigel Pharmaceuticals, Inc.	$41.79	2.1×	1.97×	2.62×	5.95×	-171.8%	93.3%	42.6%	124.7%	93.8%	28.2%	9.8%	0.14×	0.1×	17.14×	2.42×	0.0%	4	4.57	4	A
Peer median	—	-4.07×	1.97×	2.62×	-3.81×	-96.7%	77.5%	0.0%	0.0%	-33.7%	-36.3%	-18.0%	0.03×	0.37×	0×	7.02×	0.0%	2	4.57	3	—